{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:24:36Z","timestamp":1790144676974,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100006315","name":"Reumafonds","doi-asserted-by":"publisher","award":["LLP-20"],"award-info":[{"award-number":["LLP-20"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1191-y","type":"journal-article","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T08:40:18Z","timestamp":1481532018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters"],"prefix":"10.1186","volume":"18","author":[{"given":"Tamarah D.","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Blits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Vosslamber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis L.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,12]]},"reference":[{"key":"1191_CR1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/ard.2006.063412","volume":"66","author":"TC Pouw Kraan van der","year":"2007","unstructured":"van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66:1008\u201314.","journal-title":"Ann Rheum Dis."},{"key":"1191_CR2","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","volume":"17","author":"S Hervas-Stubbs","year":"2011","unstructured":"Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le BA, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011;17:2619\u201327.","journal-title":"Clin Cancer Res."},{"key":"1191_CR3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022763","volume":"6","author":"N Bacher","year":"2011","unstructured":"Bacher N, Graulich E, Jonuleit H, Grabbe S, Steinbrink K. Interferon-alpha abrogates tolerance induction by human tolerogenic dendritic cells. PLoS One. 2011;6, e22763.","journal-title":"PLoS One."},{"key":"1191_CR4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/annrheumdis-2012-202753","volume":"72","author":"J Lubbers","year":"2013","unstructured":"Lubbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013;72:776\u201380.","journal-title":"Ann Rheum Dis."},{"key":"1191_CR5","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3819","volume":"14","author":"HG Raterman","year":"2012","unstructured":"Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14:R95.","journal-title":"Arthritis Res Ther."},{"key":"1191_CR6","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.38400","volume":"66","author":"Y Sanayama","year":"2014","unstructured":"Sanayama Y, Ikeda K, Saito Y, Kagami S, Yamagata M, Furuta S, et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol. 2014;66:1421\u201331.","journal-title":"Arthritis Rheumatol."},{"key":"1191_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.gene.6364438","volume":"9","author":"TC Pouw Kraan van der","year":"2008","unstructured":"van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, Voskuyl AE, Rustenburg F, Baggen JM, et al. Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients. Genes Immun. 2008;9:16\u201322.","journal-title":"Genes Immun."},{"key":"1191_CR8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/rheumatology\/kep345","volume":"49","author":"T Cantaert","year":"2010","unstructured":"Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, et al. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford). 2010;49:156\u201366.","journal-title":"Rheumatology (Oxford)"},{"key":"1191_CR9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum."},{"key":"1191_CR10","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2014","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014."},{"key":"1191_CR11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/biostatistics\/kxp011","volume":"10","author":"MA Wiel van de","year":"2009","unstructured":"van de Wiel MA, Berkhof J, van Wieringen WN. Testing the prediction error difference between 2 predictors. Biostatistics. 2009;10:550\u201360.","journal-title":"Biostatistics."},{"key":"1191_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrmicro1126","volume":"3","author":"RG Jenner","year":"2005","unstructured":"Jenner RG, Young RA. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol. 2005;3:281\u201394.","journal-title":"Nat Rev Microbiol."},{"key":"1191_CR13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2015.01.013","volume":"14","author":"G Valesini","year":"2015","unstructured":"Valesini G, Gerardi MC, Iannuccelli C, Pacucci VA, Pendolino M, Shoenfeld Y. Citrullination and autoimmunity. Autoimmun Rev. 2015;14:490\u20137.","journal-title":"Autoimmun Rev."},{"key":"1191_CR14","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1128\/MCB.00146-10","volume":"30","author":"JR Flammer","year":"2010","unstructured":"Flammer JR, Dobrovolna J, Kennedy MA, Chinenov Y, Glass CK, Ivashkiv LB, et al. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol. 2010;30:4564\u201374.","journal-title":"Mol Cell Biol."},{"key":"1191_CR15","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794\u2013804.","journal-title":"J Immunol."},{"key":"1191_CR16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0049-0172(96)80035-7","volume":"25","author":"P Barrera","year":"1996","unstructured":"Barrera P, Boerbooms AM, van de Putte LB, van der Meer JW. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum. 1996;25:234\u201353.","journal-title":"Semin Arthritis Rheum."},{"key":"1191_CR17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1440-1681.2009.05215.x","volume":"36","author":"M Bertolotto","year":"2009","unstructured":"Bertolotto M, Dallegri F, Dapino P, Quercioli A, Pende A, Ottonello L, et al. Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: role of caspase pathway. Clin Exp Pharmacol Physiol. 2009;36:1132\u20135.","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"1191_CR18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13075-016-1065-3","volume":"18","author":"TD Jong de","year":"2016","unstructured":"de Jong TD, Lubbers J, Turk S, Vosslamber S, Mantel E, Bontkes HJ, et al. The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes. Arthritis Res Ther. 2016;18:165.","journal-title":"Arthritis Res Ther."},{"key":"1191_CR19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13075-015-0564-y","volume":"17","author":"TD Jong de","year":"2015","unstructured":"de Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ, et al. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res Ther. 2015;17:78.","journal-title":"Arthritis Res Ther."},{"key":"1191_CR20","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","volume":"70","author":"BW Higgs","year":"2011","unstructured":"Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70:2029\u201336.","journal-title":"Ann Rheum Dis."},{"key":"1191_CR21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-016-0946-9","volume":"18","author":"TD Jong de","year":"2016","unstructured":"de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TCTM, et al. Physiological evidence for diversification of IFN\u03b1- and IFN\u03b2-mediated response programs in different autoimmune diseases. Arthritis Res Ther. 2016;18:49.","journal-title":"Arthritis Res Ther."}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T01:44:29Z","timestamp":1498355069000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1191-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1191-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"290"}}